Tonix Pharmaceuticals Holding Corp.

NasdaqCM:TNXP Stock Report

Market Cap: US$47.8m

Tonix Pharmaceuticals Holding Management

Management criteria checks 3/4

Tonix Pharmaceuticals Holding's CEO is Seth Lederman, appointed in Oct 2011, has a tenure of 13.25 years. total yearly compensation is $2.05M, comprised of 32.9% salary and 67.1% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $38.28. The average tenure of the management team and the board of directors is 6.4 years and 6.3 years respectively.

Key information

Seth Lederman

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage32.9%
CEO tenure13.3yrs
CEO ownership0.00008%
Management average tenure6.4yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Seth Lederman's remuneration changed compared to Tonix Pharmaceuticals Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$135m

Jun 30 2024n/an/a

-US$149m

Mar 31 2024n/an/a

-US$99m

Dec 31 2023US$2mUS$675k

-US$117m

Sep 30 2023n/an/a

-US$123m

Jun 30 2023n/an/a

-US$124m

Mar 31 2023n/an/a

-US$123m

Dec 31 2022US$5mUS$675k

-US$117m

Sep 30 2022n/an/a

-US$112m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$98m

Dec 31 2021US$8mUS$675k

-US$92m

Sep 30 2021n/an/a

-US$80m

Jun 30 2021n/an/a

-US$73m

Mar 31 2021n/an/a

-US$64m

Dec 31 2020US$4mUS$614k

-US$52m

Sep 30 2020n/an/a

-US$46m

Jun 30 2020n/an/a

-US$42m

Mar 31 2020n/an/a

-US$34m

Dec 31 2019US$1mUS$585k

-US$31m

Sep 30 2019n/an/a

-US$31m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$29m

Dec 31 2018US$1mUS$473k

-US$29m

Compensation vs Market: Seth's total compensation ($USD2.05M) is above average for companies of similar size in the US market ($USD645.47K).

Compensation vs Earnings: Seth's compensation has been consistent with company performance over the past year.

CEO

Seth Lederman (66 yo)

13.3yrs

Tenure

US$2,050,065

Compensation

Dr. Seth Lederman, M. D., is a Co-Founder of Tonix Pharmaceuticals Holding Corp. (formerly, Krele Pharmaceuticals) and has been its Chairman, Chief Executive Officer, President and Director since October 7...

Leadership Team

NamePositionTenureCompensationOwnership
Seth Lederman
Co-Founder13.3yrsUS$2.05m0.000080%
$ 38.3
Bradley Saenger
CFO & Treasurer8.9yrsUS$904.91k0%
$ 0
Jessica Morris
Chief Operating Officer8.9yrsUS$928.60k0%
$ 0
Gregory Sullivan
Chief Medical Officer & Secretary7.8yrsUS$952.00k0.000010%
$ 4.8
Siobhan Fogarty
Executive Vice President of Product Developmentno datano datano data
Darryl Rideout
Executive Vice President of Experimental Chemistry5yrsno datano data
Sina Bavari
Executive Vice President of Infectious Disease Research & Development2.5yrsno datano data
Zeil Rosenberg
Executive Vice President of Medical2yrsno datano data
Thomas Englese
Executive Vice President of Commercial Operationsless than a yearno datano data

6.4yrs

Average Tenure

54yo

Average Age

Experienced Management: TNXP's management team is seasoned and experienced (6.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Seth Lederman
Co-Founder13.3yrsUS$2.05m0.000080%
$ 38.3
Adeoye Olukotun
Independent Director6.3yrsUS$82.48k0%
$ 0
R. Stillwell
Independent Director1.8yrsUS$113.05k0%
$ 0
David Grange
Independent Director6.9yrsUS$82.48k0%
$ 0
Margaret Bell
Independent Director7.3yrsUS$82.48k0%
$ 0
Richard Bagger
Independent Director4.6yrsUS$82.48k0%
$ 0
Iredell Iglehart
Member of Scientific Advisory Boardno datano datano data
James Treco
Independent Lead Director5.9yrsUS$102.48k0%
$ 0
Harvey Moldofsky
Member of Scientific Advisory Board13.6yrsno datano data
Carolyn Taylor
Independent Director3.5yrsUS$82.48k0%
$ 0

6.3yrs

Average Tenure

66.5yo

Average Age

Experienced Board: TNXP's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 01:13
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tonix Pharmaceuticals Holding Corp. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
David BuckB. Riley Securities, Inc.
Kumaraguru RajaBrookline Capital Markets